Missoula, MT, February 28, 2025 – Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies, is pleased to announce the appointment of Dr. Heather Madsen to its Board of Directors. Dr. Madsen, a distinguished life sciences executive and Operating Partner at Hatteras Venture Partners, brings extensive expertise in the creation of high-performing life science teams and strategic growth initiatives.
“We are thrilled to welcome Dr. Madsen to our Board,” said Dr. David Burkhart, CEO and co-founder of Inimmune. “Her diverse experience spanning early R&D to post-marketing including strategic development will be invaluable as we continue to advance our immunotherapy pipeline and expand our impact in the biotech space.”
With a background in genetics and over twenty years of experience across drug discovery and clinical development, Dr. Madsen has a deep understanding of the scientific and business landscapes that drive the success of healthcare companies. She joined Hatteras Venture Partners in 2024 to spearhead new company incubation as well as identify and support innovative biotech companies for the Hatteras portfolio. Prior to joining Hatteras, Dr. Madsen held leadership positions at GSK and ViiV Healthcare contributing to the growth and development of high-potential therapeutics, vaccines, and technologies. She is a co-author of 40 peer-reviewed scientific publications and a co-inventor of 3 patents.
“Inimmune has demonstrated remarkable progress in developing novel immunotherapies to treat allergy and cancer that have the potential to transform patient care,” said Dr. Madsen. “I look forward to working with the leadership team to support the company’s growth and help bring innovative treatments to market.”
Dr. Madsen’s appointment comes at a pivotal time for Inimmune as the company advances its clinical programs and seeks strategic partnerships to accelerate the commercialization of its groundbreaking immunotherapies.
For more information about Inimmune and its leadership team, please visit www.inimmune.com.
